The therapeutic community is abuzz with anticipation surrounding retatrutide, a new dual GIP and GLP-1 target that’s demonstrating significant potential in clinical trials for managing obesity. Unlike some available weight loss approaches, retatrutide appears to provide a greater substantial decrease in body size and benefit metabolic markers, p… Read More